Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 4
Submit an article Journal homepage
24
Views
5
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for renal cell carcinoma

Philip E Shaheen Cleveland Clinic Foundation, Experimental Therapeutics Program, Taussig Cancer Center, R33, 9500 Euclid Avenue, Cleveland, OH 44195, USA. [email protected]
&
Ronald M Bukowski Cleveland Clinic Foundation, Experimental Therapeutics Program, Taussig Cancer Center, R33, 9500 Euclid Avenue, Cleveland, OH 44195, USA. [email protected]
Pages 773-795 | Published online: 31 Oct 2005

Bibliography

  • PARKIN DM, BRAY F, FERLAY J, (2001) 94:153–156.
  • ILIOPOULOS O, ENG C: Genetic and clinical aspects of familial renal neoplasms.
  • MCLAUGHLIN JK, MANDEL JS, BLOT WJ, SCHUMAN LM, MEHL ES, FRAUMENI JF: A population-based case-control study of renal cell carcinoma. J. Natl. Cancer Inst. (1984) 72(2):275–284. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal
  • DOUBLET JD, PERALDI MN GATTEGNO B, THIBAULT P, transplant patients. J. Urol. (1997) 158:42–44.
  • DHOTE R, THIOUNN N DEBRE B, VIDAL-TRECAN G: Risk factors for adult renal cell carcinoma. Urol. Clin. North Am. (2004) 31:237–247.
  • RITCHIE AWS, DEKERNION JB: The natural history and clinical features of renal carcinoma. Semin. NephroL (1987) 7(2):131–139.
  • MEVORACH RA, SEGAL AJ TERSEGNO ME, FRANK IN: Renal cell carcinoma: incidental diagnosis and natural history: review of 235 cases. Urology (1992) 39(6):519–522.
  • WYCZOLKOWSKI M, KLIMA W, BIEDA W, WALAS K: Spontaneous regression of hepatic metastases after nephrectomy and metastasectomy of renal cell carcinoma. Urol. Int. (2001) 66:119–120.
  • EDWARDS MJ, ANDERSON JA, ANGEL JR, HARTY JI: Spontaneous regression of primary and metastatic renal cell carcinoma. J. Urol. (1996) 155(4):1385.
  • BUKOWSKI RM, NOVICK AC: Clinical practice guidelines: renal cell carcinoma. Cleve. Clin. J. Med. (1997) 64\(Suppl. 1):1–48.
  • JAVIDAN J, STRICKER J, TAMBOLI P et al.: Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J. Urol. (1999) 162:1277–1281.
  • PANTUCK AJ, ZISMAN A, BELLDEGRUN AS: The changing natural history of renal cell carcinoma. J. Urol. (2001) 166:1611–1623.
  • GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer statistics, 2000. CA Cancer J. Clin. (2000) 50(1):7–33.
  • RABINOVITCH RA, ZELEFSKY MJ, GAYNOR JJ, FUKS Z: Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J. Clin. OncoL (1994) 12(1):206–212.
  • FISHMAN M, ANTONIA S: Novel therapies for renal cell carcinoma - an update. Expert Opin. Invesng. Drugs (2003) 12(4): 593–609.
  • FINKE JH, RAYMAN P, GEORGE R et al.: Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. Clin. Cancer Res. (2001) 7(suppl):940s–946s.
  • DERWEESH IH, TANNENBAUM CS, RAYMAN PA, FINKE JH: Mechanisms of immune dysfunction in renal cell carcinoma. Cancer Treat. Res. (2003) 116:29–51.
  • GATTINONI L, ALUM, FERRARI L et al.: Renal cancer treatment: a review of the literature. Tumori (2003) 89:476–484.
  • GAMELIN E, MERTINS SD, REGIS JT et al.: Intrinsic drug resistance in primary and metastatic renal cell carcinoma. J. Urol. (1999) 162:217–224
  • MOTZER RJ: Renal cell carcinoma: a priority malignancy for development and study of novel therapies. J. Chn. Oncol (2003) 21(7):1193–1194.
  • VIEWEG J, JACKSON A: Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin. Biol. Ther. (2004) 4(11):1791–1801.
  • MCDERMOTT, ATKINS MB: Application of IL-2 and other cytokines in renal cancer. Expert Opin. Biol. Ther. (2004) 4(4):455–468.
  • BUKOWSKI RM: Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer (1997) 8(7):1198–1220.
  • FYFE G, FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, LOUIE AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy./ Clin. Oncol (1995) 13(3):688–696.
  • BAATEN G, VOOGD AC, WAGSTAFF J: A systematic review of the relation between interleukin-2 schedule and outcome inpatients with metastatic renal cell carcinoma. Eur. J. Cancer (2004) 40:1127–1144.
  • YANG JC, SHERRY RM, STEINBERG SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21(10:3127–3132.
  • MCDERMOTT DF, REGAN MM, CLARK JI et al.: Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. j Clin. Oncol (2005) 23(1):133–141.
  • MALAGUARNERA M, FERLITO L, GULIZIA G, DI FAZIO I, PISTONE G: Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature. Eur. j Clin. Pharmacol (2001) 57:267–273.
  • ATZPODIEN J, KIRCHNER H, JONAS U et al.: Interleukin-2 and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German cooperative renal carcinoma chemoimmunotherapy group (DGCIN). j Clin. Oncol (2004) 22(7):1188–1194.
  • NEGRIER S: Better survival with interleukin-2-based regimens? Possibly only in highly selected patients. J. Clin. Onol (2004) 22(7):1174–1176.
  • QUESSADA JR, RIOS A, SWANSON D,TROWN P, GUTTERMAN JU: Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. (1985) 3(11):1522–1528.
  • KANKURI M, PELLINIEMI TT, PYRHONEN S, NIKKANEN V, HELENIUS H, SALMINEN E: Feasibility of prolonged use of interferon-a in metastatic kidney carcinoma. Cancer (2001) 92:761–767.
  • KIRWOOD J: Cancer immunotherapy: the interferon-a experience. Semin. Oncol (2002) 29(3):18–26.
  • ATZPODIEN J, HOFFMANN R, FRANZKE M, STIEF C, WANDERT T, REITZ M: Thirteen-year, long-term efficacy of interferon 2a and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer (2002) 95:1045–1050.
  • KRIEGMAIR M, OBERNEDER R, HOFSTETTER k Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology (1995) 45(5):758–762.
  • NO AUTHORS LISTED: Medical research Council and Collaborators: interferon alfa and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet (1999) 353:14–17.
  • HERNBERG M, PYRHONEN S, MUHONEN T: Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. Immunother. (1999) 22(2):145–154.
  • MOTZER RJ, RAKHIT A, THOMPSON J et al.: Phase II trial of branched peginterferon-a, (40 kDa) for patients with advanced renal cell carcinoma. Ann. Oncol (2002) 13:1799–1805.
  • BUKOWSKI R, ERNSTOFF MS, GORE ME et al.: Pegylated interferon alpfa-26 treatment for patients with solid tumors: a Phase I/II study. J. Clin. Oncol (2002) 20(18):3841–3849.
  • MESSING EM, MANOLA J, WILDING G et al.: Phase II study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An eastern cooperative oncology group/intergroup trial. J. Clin. Onol. (2003) 21(7):1214–1222.
  • PIZZOCARO G, PIVA L, COLAVITA M et al.: Interferon adjuvant to radical nephrectomy in robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol (2001) 19(2):425–431.
  • FANELLI M, SARMIENTO R, GATTUSO et al.: Thalidomide: a new anticancer drug? Expert Opin. Investig. Drugs (2003) 12(7):1211–1225.
  • DALIANI DD, PAPANDREOU CN, THALL PF et al.: A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer (2002) 95:758–765.
  • MINOR DR, MONROE D, DAMICO LA, MENG G, SURYADEVARA U, ELIAS L: A Phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest. New Drugs (2002) 20:389–393.
  • AMATO RJ: Thalidomide therapy for renal cell carcinoma. Crit. Rev. Oncol Hematol (2003) 46(suppl):559–565.
  • HERNBERG M, VIRKKUNEN P, BONO P, AHTINEN H, MAENPAA H, JOENSUU H: Interferon alfa-26 three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. Clin. Oncol. (2003) 21(20):3770–3776.
  • GORDON MS, MANOLA J, FAIRCLOUGH D et al.: Low dose interferon-an (IFN) + thalidomide (T) inpatients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A Phase III study of the Eastern Cooperative Oncology Group (E2898). Proc. Am. Soc. Clin. Oncol (2004):A4516.
  • YAGODA A, ABI-RACHED B, PETRYLAK D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol (1995) 22(1):42–60.
  • NANUS DM, GARINO A, MILOWSKY MI, LARKIN M, DUTCHER JP: Active chemotherapy for sarcomatoid and rapidly progressing renal call carcinoma. Cancer (2004) 101(7):1545–1551.
  • RATHMELL WK, MALKOWICZ SB, HOLROYDE C, LUGINBUHL W, VAUGHN DJ: Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. Am. J. Clin. Oncol (2004) 27(2):109–112.
  • RAVAUD A, TRUFFLANDIER N, FERRIERE JM et al.: Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a Phase II trial. Br. J. Cancer (2003) 89:2213–2218.
  • WENZEL C, LOCKER GJ, BARTSCH R et al.: Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anti-Cancer Drugs (2003) 14(10):779–784.
  • HRUSHESKY WJ, VON ROEMELING R, LANNING RM, RABATIN JT: Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J. Clin. Oncol (1990) 8(9):1504–1513.
  • DAMASCELLI B, MARCHIANO A, SPREAFICO C et al.: Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. Cancer (1990) 66(2):237–241.
  • CONROY T, GEOFFROIS L, GUILLEMIN F et al.: Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer (1993) 72(7):2190–2197.
  • REESE DM, CORRY M, SMALL EJ: Infusional loxuridine-based therapy for patients with metastatic renal cell carcinoma. Cancer (2000) 88(6):1310–1316.
  • HAAS NB, GIANTONIO BJ, LITWIN S et al.: Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a Phase II trial of the Fox Chase Network. Cancer (2003) 98(9):1837–1841.
  • WARNER E, TOBE SW, ANDRULIS IL, PEI Y, TRACHTENBERG J, SKORECKI KL: Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am. J. Clin. Oncol (1995) 18(3):251–256.
  • PYRHONEN S, SALMINEN E, RUUTU M et al.: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone inpatients with advanced renal cell carcinoma. J. Clin. Oncol (1999) 17(9):2859–2867.
  • MERTENS WC, EISENHAUER EA, MOORE M et al.: Gemcitabine in advanced renal cell carcinoma. A Phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol (1993) 4(4):331–332.
  • DE MULDER PH, WEISSBACH L, JAKSE G, OSIEKA R, BLATTER J: Gemcitabine: a Phase II study in patients with advanced renal cancer. Cancer Chemother. Pharmacol (1996) 37(5):491–495.
  • PORTA C, ZIMATORE M, IMARISIO I et al.: Gemcitabine and oxaplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma. Final results of a single-institution Phase II study. Cancer (2004) 100:2132–2138.
  • WATERS JS, MOSS C, PYLE L et al.: Phase II clinical trial of capcitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br. J. Cancer (2004) 91(10):1763–1768.
  • RINI BI, VOGELZANG NJ, DUMAS MC, WADE III JL, TABER DA, STADLER WM : Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. J. Clin. Oncol (2000) 18(12):2419–2426.
  • RYAN CW, VOGELZANG NJ, STADLER WM: A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer (2002) 94(10):2602–2609.
  • NERI B, DONI L, GEMELLI MT et al.: Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal call cancer. J. Urol (2002) 168(3):956–958.
  • CUMMINGS J, SMYTH JF: DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann. Oncol (1993) 4(7):533–543.
  • RAMP U, MAHOTKA C, KALINSKI T, EBEL E, GABBERT HE, GERHARZ CD: Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types. Anti-Cancer Res. (2001) 21(5):3509–3517.
  • LAW TM, ILSON DH, MOTZER RJ: Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest. New Drugs (1994) 12(2):143–145.
  • BRAYBROOKE JP, O'BYRNE KJ, PROPPER DJ et al.: A Phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin. Cancer Res. (2000) 6:4679–4704.
  • FIZAZI K, ROLLAND F, CHEVREAU C et al.: A Phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer (2003) 98(1):61–65.
  • MILLAR AW, LYNCH KP: Rethinking clinical trials for cytostatic drugs. Nat. Rev. Cancer (2003) 3(7):540–545.
  • HOEKSTRA R, VERWEIJ J, ESKENS FA: Clinical trial design for target specific anticancer agents. Invest. New Drugs (2003) 21:243–250.
  • STRIGLEY JR, HUTTER RVP, GELB AB et al.: Current prognostic factors-renal cell carcinoma. Workgroup No. 4. Cancer (1997) 80(5):994–996.
  • KATTAN MW, REUTER V, MOTZER RJ, KATZ J, RUSSO P: A postoperative prognostic nomogram for renal cell carcinoma. J. Urol (2001) 166:63–67.
  • ZISMAN A, PANTUCK AJ, DOREY F et al.: Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol (2001) 19(6):1649–1657.
  • FRANK I, BLUTE ML, CHEVILLE JC, LOHSE CM, WEAVER AL, ZINCKE H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol (2002) 168:2395–2400.
  • MOTZER RJ, MAZUMDAR M, BACIK J, BERG W, AMSTERDAM A, FERRARA J: Survival and prognostic stratification of 670 patients with advanced renal call carcinoma. J. Clin. Oncol. (1999) 17(8):2530–2540.
  • MOTZER RJ, BACIK J, MURPHY BA, RUSSO P, MAZUMDAR M: Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol (2002) 20(1):289–296.
  • MEKHAIL TM, ABOU-JAWDE RM, BOUMERHI G et al.: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival inpatients with previously untreated metastatic renal cell carcinoma. Clin. Oncol (2005) 23(4):832–841.
  • MEKHAIL TM, KAWANISHI-TABATA R, TUBBS R et al.: Renal cell carcinoma (RCC) and telomerase activity: relationship to stage. Urol Oncol Semin. Orig. Invest. (2003) 21:424–430.
  • NEMOTO K, KONDO Y, HIMENO S et al.: Modulation of telomerase activity by zinc in human prostatic and renal cancer cells. Biochem. Pharmacol (2000) 59(4):401–405.
  • FURGE KA, LUCAS KA, TAKAHASHI M et al.: Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res. (2004) 64:4117–4121.
  • TAKAHASHI M, RHODES DR, FURGE KA et al.: Gene expression profiling of clear renal cell carcinoma: gene identification and prognostic classification. Proc. Natl. Acad. Sci. USA (2001) 98(17):9754–9759.
  • MOCH H, SAUTER G, BUCHHOLZ N et al.: Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum. Pathol (1997) 28(11):1255–1259.
  • UHLMAN DL, NGUYEN P, MANIVEL JC et al.: Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin. Cancer. Res. (1995) 1(8):913–920.
  • GNARRA JR, TORY K, WENG Y et al.: Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat. Genet. (1994) 7(1):85–90.
  • ALLEMAN WG, TABIOS RL, CHANDRAMOULI GV et al.: The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine. Clin. Cancer. Res. (2004) 10(20):7011–7021.
  • ZBAR B: Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv. (1995) 25:219–232.
  • CLIFFORD SC, ASTUTI D, HOOPER L, HAXWELL PH, RATCLIFFE PJ, MAHER ER: The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbxl and HIF-la in renal cell carcinoma. Oncogene (2001) 20:5067–5074.
  • NA X, WU G, RYAN CK, SCHOEN SR, DI'SANTAGNESE PA, MESSING EM: Overproduction of vascular endothelial growth factor related to Von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-la expression in renal cell carcinomas. J. Urol (2003) 170:588–592.
  • BUI MHT, VISAPAA H, SELIGSON D et al.: Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma. Urol (2004) 171:2461–2466.
  • ZAVADA J, ZAVADOVA Z, ZAT'OVICOVA M, HYRSL L, KAWACIUK I: Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br. J. Cancer (2003) 89:1067–1071.
  • ATKINS M, MCDERMOTT D, MIER J et al.: High carbonic anhydrase IX expression predicts for renal cancer response to IL-2 therapy. J. Immunother. (2003) 26(6):539.
  • IVANOV SV, KUZMIN I, WEI MH et al.:Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type Von Hippel-Lindau transgenes. Proc. Natl Acad. St-Z. (1998) 95:12596–12601.
  • BISMAR TA, BIANCO FJ, ZHANG H et al.: Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections. Pathology (2003) 3(0:513–517.
  • MUKOUYAMA H, JANZEN NK, HERNANDEZ JM et al.: Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with recombinant adenovirus encoding carbonic anhydrase 9. Clin. Cancer Res. (2004) 10:1421–1429.
  • NAITO S, KOGA H, YOKOMIZO A et al.: Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World J. Surg-. (2000) 24(10):1183–1186
  • SCHELTEMA JMW, ROMIJN JC, VAN STEENBRUGGE GJ, SCHRODER FH, MICKISCH GH: Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells. Anti-Cancer Res. (2001) 2:3161–3166.
  • MOLTO L, RAYMAN P, PASZKIEWICZ-KOZIK E et al.: The Bc1-2 ransgene protects T cells from renal cell carcinoma-mediated apoptosis. Clin. Cancer Res. (2003) 9:4060–4068.
  • OUDARD S, LEVALOIS C, ANDRIEU JM et al.: Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anti-Cancer Res. (2002) 22:121–128.
  • SYED S, TOLCHER AW: Novel therapies for renal cell carcinoma. Cancer Treat. Res. (2003) 116:227–238.
  • BERG WJ, DIVGI CR, NANUS DM, MOTZER RJ: Novel investigative approaches for advanced renal cell carcinoma. Semin. Oncol (2000) 27:234–239
  • HERBST RS, SHIN DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer (2002) 94(5):1593–1611.
  • HOFMOCKEL G, RIESS S, BASSUKAS ID, DAMMRICH J: Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact. Eur. Urol (1997) 31(4):478–484.
  • YANG XD, JIA XC, CORVALAN JR, WANG P, DAVIS CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol Hematol (2001) 38(1):17–23.
  • FOON KA, YANG XD, WEINER LM et al.: Peclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiation Oncology Biol. Phys. (2004) 58(3):984–990.
  • ROWINSKY EK, SCHWARTZ GH, GOLLOB JA et al.: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. Clin. Oncol. (2004) 22(15):3003–3015.
  • DANCEY JE: Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mousetrap? Clin. Oncol. (2004) 22(15):2975–2977.
  • MOTZER RJ, AMATO R, TODD M et al.: Phase II trial of epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest. New Drugs (2003) 21:99–101.
  • ASAKUMA J, SUMITOMO M, ASANO T, ASANO T, HAYAKAWA M: Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. J. Urol. (2004) 171:897–902.
  • DRUCKER B, BACIK J, GINSBERG M et al.: Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest. New Drugs (2003) 21(3):341–345.
  • DAWSON NA, GUO C, ZAK R et al.: A Phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin. Cancer Res. (2004) 10(23):7812–7819.
  • AKITA RW, SLIWKOWSKI MX: Preclinical studies with Erlotinib (Tarceva). Semin. Oncol (2003) 30(3 suppl 7):15–24.
  • SOULIERS D, SENZER NN, VOKES EE, HIDALGO M, AGARWALA SS, SIU LL: Multicenter Phase II study of erlotinib, and oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with reccurent or metastatic squamous cell cancer of the head and neck. J. Clin. Onol. (2004) 22(1):77–85.
  • DURKIN AJ, BLOOMSTON PM, ROSEMURGY et al.: Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am. J. Surg-. (2003) 186(5):431–436.
  • BEERAM M, ROWINSKY EK, WEISS GR et al.: A Phase II, pharmacokinetic (PK) and biological correlative study of OSI-774 (Tarceva) in patients with advanced renal cell carcinoma, with PDG-PET imaging: evidence of durable stable disease and antitumor activity. Eur. J. Cancer Suppl (2004) 2(8):111.
  • SPIGEL DR, HAINS WORTH JD, SOSMAN JA et al.: Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a Phase II multicenter trial. Proc. Am. Soc. Clin. Onol. (2005) 23(165):A4545. Also presented at the 4Ist ASCO 2005 annual meeting. Orlando, Florida, US (2005).
  • X1A W, MULLIN RJ, KEITH BR et al.: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor bloks EGF activation of RGFRJerbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21(41):6255–6263.
  • BENCE AK, ANDERSON EB, HALEPOTA MA et al.: Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest. New Drugs (2005) 23(1):39–49.
  • VERSOLA M, BURRIS HA, JONES S et al.: Clinical activity of GW572016 in EGF10003 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2004):A3047.
  • MINAMI H, NAKAGAWA K, KAWADA K et al.: A Phase I study of GW572016 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2004) 22(145):3048.
  • YANG CC, CHU KC, YEH WM: Expression of vascular endothelial growth factor I renal cell carcinoma is correlated with cancer advancement. J. Cin. Lab. Anal. (2003) 17:85–89.
  • SYED S, TOLCHER AW: Novel therapies for renal cell carcinoma. Cancer Treat. Res. (2003) 116:227–238.
  • FOLKMAN J, SHING Y: Angiogenesis. J. Biol. Chem. (1992) 267:10931–10934.
  • YOSHINO S, KATO M OKADA K: Prognostic significance of microvessel count in low stage renal cell carcinoma. Int. J. Urol. (1995) 2(3):156–160.
  • YIHAI C: Antiangiogenic cancer therapy. Semin. cancer Biol. (2004) 14(2):139–145.
  • ELICEIRI BP, CHERESH DA: The role of ocv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. (1999) 103(9):1227–1230.
  • YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl. J. Med. (2003) 349(5):427–434.
  • HOSANG M: Suramin binds to platelet-derived growth factor and inhibits its biological activity. J. Cell. Biochem. (1985) 29:265–273.
  • RIFKIN DB, MOSCATELLI D: Recent developments in the cell biology of basic fibroblast growth factor. J. Cell Biol. (1989) 109:1–6.
  • MYERS RB, PARKER M, GRIZZLE WE: The effects of coumarin and suramin on the growth of malignant renal and prostatic cell lines./ Cancer Res. Clin. Oncol (1994) 120(suppl):S11–S13.
  • LA ROCCA RV, STEIN CA, DANESI R, COOPER MR, UHRICH M, MYERS CE: A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer (1991) 67:1509–1513.
  • DREICER R, SMITH DC, WILLIAMS RD, SEE WA: Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest. New Drugs (1999) 17:183–186.
  • MOTZER RJ, NANUS DM, O'MOORE P et al.: Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res. (1992) 52(20):5775–5779.
  • RAMAKRISHNAN V, BHASKAR V, LAW DA et al.: M200, an integrin a5131 antibody, promotes apoptosis in proliferating endothelial cells. Proc. Am. Soc. Clin. Oncol (2004) 22(14S):3187.
  • RICART A, LIU G, TOLCHER A et al.: A Phase I dose-escalation study of anti-a5131 integrin monoclonal antibody (M200) in patients with refractory solid tumors. Eur. J. Cancer (2004) 2(8):52.
  • ZWICK E, BANGE J, ULLRICH A: Receptor tyrosine kinases as targets for anticancer drugs. Trends. Mo/. Med. (2002) 8(1):17–23.
  • WILHELM SM, CARTER C, TANG L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. (2004) 64:7099–7109
  • AHMAD T, EISEN T: Kinase inhibition with BAY 43–9006 in renal cell carcinoma. Clin. Cancer Res. (2004) 10(suppl.):56388–56392.
  • STRUMBERG D, VOLIOTIS D, MOELLER JG et al.: Results of Phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int. J. Clin. Pharmacol Ther. (2002) 40(12):580–581.
  • LEE JT, MCCUBREY JA: BAY-43-9006 Bayer/Onyx. Curr. Opin. Investig. Drugs (2003) 4(0:757–763.
  • RATAIN MJ, EISEN T, STADLER WM et al.: Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol (2005) 23(165):A4544. Also presented at the 4Ist ASCO 2005 annual meeting. Orlando, Florida, US (2005).
  • Onyx Pharmaceuticals Press Release (2004).
  • ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. OncoL (2005) 23(16S):A4510. Also presented at the 41st ASCO 2005 annual meeting. Orlando, Florida, US (2005).
  • MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU011248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327–337.
  • ABRAMS TJ, LEE LB, MURRAY LJ, PRYER NK, CHERRINGTON JM: SU011248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. MoL Cancer Ther. (2003) 2(5):471–478.
  • ABRAMS TJ, MURRAY LJ, PESENTI E et al.: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. MoL Cancer Ther. (2003) 2(10):1011–1021.
  • MOTZER RJ, RINI BI, MICHAELSON MD et al.: Phase II trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. (2005) 23(165):A4508. Also presented at the 41st ASCO 2005 annual meeting. Orlando, Florida, US (2005).
  • RUGO HS, HERBST RS, LIU G et al.: Clinical and dynamic imaging results of the first Phase I study of AG-013736, an oral anti-angiogenesis agent, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2004) 22(145):A2503.
  • RINI B, RIXE O, BUKOWSKI M et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase II study of cytokine-refractory, metastatic renal call carcinoma (RCC). Proc. Am. Soc. Clin. OncoL (2005) 23(165):A4509. Also presented at the 41st ASCO 2005 annual meeting. Orlando, Florida, US (2005).
  • SUTTLE AB, HURWITZ H, DOWLATI A et al.: Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2004) 22(145):A3054.
  • DUBKIN L, DILLING MB, CHESHIRE PJ et al.: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. (2001) 7:1758–1764.
  • HUDSON CC, LIU M, CHIANG GG et al.: Regulation of hypoxia-inducible factor la expression and function by the mammalian target of rapamycin. MoL Cell. Biol. (2002) 22(20):7004–7014.
  • GUBA M, VON BREITENBUCH P, STEINBAUER M et al.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. (2002) 8(2):128–135.
  • RAYMOND E, ALEXANDRE J, FAIVRE S et al.: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. (2004) 22(12):2336–2347.
  • ATKINS MB, HIDALGO M, STADLER WM et al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Clin. OncoL (2004) 22(5):909–918.
  • SMITH JY KO YJ, DUTCHER J et al.: Update of a Phase I study of intravenous CCI-779 given in combination with interferon-a to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. OncoL (2004) 22(145):A4513.
  • BOULAY A, ZUMSTEIN-MECKER S, STEPHAN C et al.: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. (2004) 64(1):252–261.
  • DI CASIMO S, MATAR P, ROJO F et al.: Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001). Proc. Am. Soc. Clin. Oncol. (2004) 22(145):A3074.
  • PACEY S, READ, STEVEN N et al.: Results of a Phase I clinical trial investigating a combination of the oral mTOR-inhibitor everolimus (E, RAD001) and gemcitabine (GEM) in patients (pts) with advanced cancers. Proc. Am. Soc. Clin. OncoL (2004) 22(14S):A3120.
  • MEDINGER M, MROSS K, ZIRRGIEBEL U et al.: Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastasis. Proc. Am. Soc. Clin. OncoL (2004) 22(145):A3055.
  • KUENEN BC, TABERNERO J, BASELGA J et al.: Efficacy and toxicity of the angiogenesis inhibitor 5U5416 as a single agent in patient with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. (2003) 9:1648–1655.
  • JENNENS RR, ROSENTHAL MA, LINDEMAN GJ, MICHAEL M: Complete radiological and metabolic response of metastatic renal cell carcinoma to 5U5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. UroL OncoL (2004) 22:193–196.
  • LARA PN, QUINN DI, MARGOLIN K et al.: 5U5416 plus interferon a in advanced renal cell carcinoma: a Phase II California Cancer Consotium study with biological and imaging correlates of angiogenesis inhibition. Clin. Cancer Res. (2003) 9:4772–4781.
  • KUENEN BC, ROSEN L, SMIT EF et al.: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and 5U5416 in patients with solid tumors. Clin. OncoL (2002) 20:1657–1667.
  • RAWAT A, NEEDLE MN, MILES B, AMATO RJ: Phase II study of CC-5013 in patients (pts) with renal cell cancer (MRCC). Proc. Am. Soc. Clin. OncoL (2005) 23(165):A4604. Also presented at the 41st ASCO 2005 annual meeting. Orlando, Florida, US (2005).
  • DAVIS NB, TABER DA, ANSARI RH et al.: Phase II trial of PS-341 inpatients with renal cell cancer: a University of Chicago Phase II consortium study. Clin. Oncol. (2004) 22(1):115–119.
  • KONDAGUNTA GV, DRUCKER B, DRUCKER B et al.: Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. (2004) 22(18):3720–3725.
  • VARADHACHARY A, WOLF JS, PETRAK K et al.: Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int. J. Cancer (2004) 111(3):398–403.
  • HAYES TG, VARADHACHARY GR, SMITH D, HINTZ D, VARADHACHARY A, FALCHOOK G: Phase I/II clinical trial of oral recombinant human lactoferrin in the treatment of chemotherapy resistant tumors. Proc. Am. Soc. Clin. Oncol (2003) 22:A947.
  • HAYES TG, VARADHACHARY GR, FALCHOOK G, SMITH D, VARADHACHARY A, DHINGRA HM: Oral recombinant human lactoferrin (rhLF) slows tumor growth in metastatic NSCLC and other advanced incurable cancers: results of a Phase II study. Proc. Am. Soc. Clin. Oncol (2004) 22(145):A3140.
  • TRIKHA M, CORRINGHAM R, KLEIN B, ROSSI JF: Targeted anti-interleukin-6 monoclonal therapy for cancer: a review of the rational and clinical evidence. Clin. Cancer Res. (2003) 9(13):4653–4665.
  • PRABHAKAR U, JANG H, PAO Q et al.: Correlation of serum CNTO 328-anti IL-6 monoclonal antibody (MAb) concentrations and biomarker expression in renal cell carcinoma (RCC) patients. Proc. Am. Soc. Clin. Oncol (2004) 22(145):A2560.
  • CORRINGHAM R: Targeting IL-6 and TNF cytokines in kidney cancer. Presented at The 4th International Congress on Monoclonal Antibodies in Cancer. Colorado Springs, CO, USA (2004).
  • MAISEY NR, HALL K, LEE C et al.: Infliximab: A Phase II trial of the tumour necrosis factor (TNFa) moniclonal antibody in patients with advanced renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol (2004) 22(145):A4514.
  • GRABMAIER K, VISSERS JLM, DE WEIJERT MCA et al.: Molecular cloning and immunogenecity of renal cell carcinoma-associated antigen G250. Int. J. Cancer (2000) 85:865–870.
  • STEFFENS MG, BOERMAN OC, DEMULDER PH et al.: Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin. Cancer Res. (1999) 5(10 Suppl. 0:32685–32745.
  • WISEMAN GA, SCOTT AM, LEE F et al. Chimeric G250 (cG250) monoclonal antibody Phase I dose escalation trial in patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol (2001) 20(1):A1027.
  • LUITEN RM, CONEY LR, FLEUREN GJ, WARNAAR SO, LITVINOV SV: Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br. J. Cancer (1996) 74(5):735–744.
  • BEVAN P, MALA C, KINDLER M et al.: Results of a Phase I/II study with monoclonal antibody CG250 in combination with IFN a-2A in metastatic renal cell carcinoma patients. Proc. Am. Soc. Clin. Oncol (2004) 22(145):A4606.
  • DAVIS ID, LIU Z, SAUNDERS W et al.: A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients (pts) with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol (2004) 22(145):A2558.
  • SANDLER AD, CHIHARA H, KOBAYASHI G et al.: CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. (2003) 63:394–399.
  • THOMPSON JA, KUZEL T, BUKOWSKI R, MASCIARI F, SCHMALBACH T: Phase lb trial of targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol (2004) 22(145):A4644.
  • HWANG JJ, PARKS, AMIN A et al.: A Phase I study of HYB2055 inpatients (pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. (2004) 22(145):A3111.
  • MOORE DJ, HWANG J, MCGREIVY J et al.: Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2005) 23(165):A2503.
  • AVIGAN D, VASIR B, GONG J et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. (2004) 10:4699–4708.
  • AVIGAN DE, GEORGE DJ, KANTOFF PW et al.: Interim safety and efficacy results from a Phase I/II study of vaccination with electrofused allogenic dentritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. Proc. Am. Soc. Clin. Oncol (2004) 22(145):A2526.
  • JOCHAM D, RICHTER A, HOFFMANN L et al.: Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomized controlled trial. Lancet (2004) 363:594–599.
  • CASTELLI C, RIVOLTINI L, RINI F et al.: Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother. (2004) 53:227–233.
  • AMATO R, MURRAY L, WOOD L, SAVARY C, TOMASOVIC S, REITSMA D: Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein-peptide complex-96 (HSPP-96) vaccine. Proc. Am. Soc. Clin. Oncol (2000) 21:A1782.
  • AMATO R, WOOD L, SAVARY C et al.: Patients with renal cell carcinoma (RCC) using autologous tumor-derived heat shock protein-peptide complex (HSPPC-96) with or without interleukin-2 (IL-2). Proc. Am. Soc. Clin. Oncol. (2000):1782.
  • TANI K, AZUMA M, NAKAZAKI Y et al.: Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther. (2004) 10(4):799–816.
  • NOONBERG SB, BENZ CC: Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs (2000) 59(4):753–767.

Websites

  • http://www.cancer.org/downloads/PRO/CancercY420Statistic0/4202004.pptAmerican Cancer Society (2004).
  • http://www.egfr-info.com/article/ 501749.aspx.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.